2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptoms
2021
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews 2021, 99: 102241. PMID: 34174668, DOI: 10.1016/j.ctrv.2021.102241.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentTreatment alterationsCIPN severityPeripheral neuropathyPatient factorsChemotherapy treatmentRelative dose intensityClinical Oncology guidelinesNeurotoxic chemotherapyDose intensityProspective trialOncology guidelinesRetrospective analysisAdult cancersIndividual patientsInconsistent recommendationsPatientsTreatment efficacyClinical decisionSeverityNeuropathyAmerican SocietyTreatmentCliniciansTreating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Blow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integrative Cancer Therapies 2021, 20: 15347354211032283. PMID: 34259084, PMCID: PMC8283040, DOI: 10.1177/15347354211032283.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerSodium-glucose co-transporter-2 inhibitorsLow-carbohydrate dietCase seriesCarbohydrate dietHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Sodium-Glucose CoTransporter 2 inhibitorsTarget adverse effectsFactor receptor 2Postmenopausal womenTreatment delayPharmacologic interventionsBreast cancerDose reductionReceptor 2HyperglycemiaTreatment efficacyHormone receptorsAdverse effectsAlpelisibSelective phosphatidylinositolTherapy